WO2001012170A3 - Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue - Google Patents

Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue Download PDF

Info

Publication number
WO2001012170A3
WO2001012170A3 PCT/US2000/022338 US0022338W WO0112170A3 WO 2001012170 A3 WO2001012170 A3 WO 2001012170A3 US 0022338 W US0022338 W US 0022338W WO 0112170 A3 WO0112170 A3 WO 0112170A3
Authority
WO
WIPO (PCT)
Prior art keywords
multiple sclerosis
attention deficit
hyperactivity disorder
deficit hyperactivity
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/022338
Other languages
French (fr)
Other versions
WO2001012170A2 (en
Inventor
Matthew S Miller
Thomas E Scammell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HK03103227.6A priority Critical patent/HK1051006B/en
Priority to DK00954081T priority patent/DK1253918T3/en
Priority to BRPI0013555-0A priority patent/BR0013555A/en
Priority to CA2380673A priority patent/CA2380673C/en
Priority to JP2001516516A priority patent/JP5542291B2/en
Priority to MXPA02001587A priority patent/MXPA02001587A/en
Priority to EP00954081A priority patent/EP1253918B1/en
Priority to DE60040487T priority patent/DE60040487D1/en
Priority to IL14779400A priority patent/IL147794A0/en
Application filed by Cephalon LLC filed Critical Cephalon LLC
Priority to AU66424/00A priority patent/AU778360B2/en
Priority to NZ516767A priority patent/NZ516767A/en
Publication of WO2001012170A2 publication Critical patent/WO2001012170A2/en
Priority to IL147794A priority patent/IL147794A/en
Priority to NO20020772A priority patent/NO331307B1/en
Anticipated expiration legal-status Critical
Publication of WO2001012170A3 publication Critical patent/WO2001012170A3/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Modafinil is effective in improving symptoms of attention deficit hyperactivity disorder and symptoms of multiple sclerosis fatigue. The administration of modafinil is also shown to activate the tuberomamillary neurons of the posterior hypothalamus, and thus exhibits activity in an area of the brain associated with normal wakefulness functions. A method of identifying a compound that selectively modulates activity of the tuberomamillary nuclues of the posterior hypothalamus is also disclosed.
PCT/US2000/022338 1999-08-16 2000-08-16 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue Ceased WO2001012170A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
IL14779400A IL147794A0 (en) 1999-08-16 2000-08-16 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
BRPI0013555-0A BR0013555A (en) 1999-08-16 2000-08-16 compositions including modafinil for the treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
CA2380673A CA2380673C (en) 1999-08-16 2000-08-16 Compositions comprising modafinil for treatment of attention deficit hyperactivity disorder
JP2001516516A JP5542291B2 (en) 1999-08-16 2000-08-16 Composition comprising modafinil for the treatment of hyperattention disorder and multiple sclerosis fatigue
MXPA02001587A MXPA02001587A (en) 1999-08-16 2000-08-16 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue.
EP00954081A EP1253918B1 (en) 1999-08-16 2000-08-16 Compositions comprising modafinil for the treatment of attention deficit hyperactivity disorder
DE60040487T DE60040487D1 (en) 1999-08-16 2000-08-16 MODAFIN COMPOSITION FOR TREATING ATTENTION DEFICIT SYNDROME / HYPERACTIVITY
HK03103227.6A HK1051006B (en) 1999-08-16 2000-08-16 Compositions comprising modafinil for the treatment attention deficit hyperactivity disorder
AU66424/00A AU778360B2 (en) 1999-08-16 2000-08-16 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
DK00954081T DK1253918T3 (en) 1999-08-16 2000-08-16 Compounds containing modafinil for the treatment of attention and activity disorders (Attention Deficit Hyperactivity Disorder (ADHD))
NZ516767A NZ516767A (en) 1999-08-16 2000-08-16 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
IL147794A IL147794A (en) 1999-08-16 2002-01-23 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
NO20020772A NO331307B1 (en) 1999-08-16 2002-02-15 Use of modafinil for the manufacture of a medicament for the treatment of attention-deficit hyperactivity disorder

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14961299P 1999-08-16 1999-08-16
US60/149,612 1999-08-16
US09/638,353 2000-08-15
US09/638,353 US6346548B1 (en) 1999-08-16 2000-08-15 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue

Publications (2)

Publication Number Publication Date
WO2001012170A2 WO2001012170A2 (en) 2001-02-22
WO2001012170A3 true WO2001012170A3 (en) 2002-09-06

Family

ID=26846889

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/022338 Ceased WO2001012170A2 (en) 1999-08-16 2000-08-16 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue

Country Status (19)

Country Link
US (3) US6346548B1 (en)
EP (1) EP1253918B1 (en)
JP (1) JP5542291B2 (en)
KR (1) KR100728080B1 (en)
CN (1) CN100450475C (en)
AT (1) ATE410157T1 (en)
AU (1) AU778360B2 (en)
BR (1) BR0013555A (en)
CA (2) CA2689735A1 (en)
CY (1) CY1109079T1 (en)
DE (1) DE60040487D1 (en)
DK (1) DK1253918T3 (en)
ES (1) ES2313902T3 (en)
IL (2) IL147794A0 (en)
MX (1) MXPA02001587A (en)
NO (1) NO331307B1 (en)
NZ (1) NZ516767A (en)
PT (1) PT1253918E (en)
WO (1) WO2001012170A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7649020B2 (en) 2002-08-09 2010-01-19 Cephalon France Modafinil polymorphic forms

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804322B1 (en) * 2000-01-31 2002-04-19 Lafon Labor USE OF MODAFINIL FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR CORRECTING VIGILANCE DISORDERS ASSOCIATED WITH MYOPATHIES
US20010034373A1 (en) * 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function
CZ2003529A3 (en) * 2000-07-27 2003-09-17 Teva Pharmaceutical Industries Ltd. Crystalline and pure modafinil and process for preparing thereof
US6919378B2 (en) * 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US7141555B2 (en) * 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
US7704975B2 (en) * 2000-12-19 2010-04-27 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
ATE357228T1 (en) * 2001-05-25 2007-04-15 Cephalon Inc SOLID PHARMACEUTICAL FORMULATION CONTAINING MODAFINIL
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
EP1401484A1 (en) 2001-06-11 2004-03-31 Transition Therapeutics Inc. Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US6821979B2 (en) * 2002-03-07 2004-11-23 Blanchette Rockefeller Neurosciences Institute Synergistic enhancement of cognitive ability
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
CN101606916B (en) * 2002-09-13 2011-02-09 赛福伦公司 Pharmaceutical formulations of modafinil and its uses
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
IL153098A0 (en) * 2002-11-26 2003-06-24 Chemagis Ltd Pharmaceutical compositions containing modafinil
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
AR045423A1 (en) * 2003-05-13 2005-10-26 Cephalon Inc COMBINATIONS OF ANALYTICS AND ANTIDEPRESSANTS
AR046410A1 (en) * 2003-09-18 2005-12-07 Cephalon Inc PHARMACEUTICAL COMPOSITIONS FOR MODIFIED LIBERATION OF MODAFINILO
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US20050137264A1 (en) * 2003-12-22 2005-06-23 Patel Ashish A. Modafinil compositions
US7423176B2 (en) * 2004-04-13 2008-09-09 Cephalon, Inc. Bicyclic aromatic sulfinyl derivatives
US7119214B2 (en) * 2004-04-13 2006-10-10 Cephalon France Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
US7297817B2 (en) * 2004-04-13 2007-11-20 Cephalon France Thio-substituted arylmethanesulfinyl derivatives
US7314875B2 (en) * 2004-04-13 2008-01-01 Cephalon, Inc. Tricyclic aromatic and bis-phenyl sulfinyl derivatives
US7449481B2 (en) * 2004-04-13 2008-11-11 Cephalon, Inc. Thio-substituted biaryl-methanesulfinyl derivatives
EP1586560A1 (en) * 2004-04-13 2005-10-19 Cephalon, Inc. Thio-substituted arylmethanesulfinyl derivatives
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
WO2006032146A1 (en) * 2004-09-24 2006-03-30 Centre For Addiction And Mental Health The use of a modafinil compound for the treatment of problem gambling
ES2646326T3 (en) * 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
EP1988898A2 (en) * 2006-02-18 2008-11-12 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
BRPI0712039A2 (en) * 2006-05-09 2011-12-20 Boehringer Ingelheim Int use of flibanserin for the treatment of postmenopausal sexual desire disorders
JP2009541443A (en) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Flibanserin for the treatment of urinary incontinence and related diseases
KR20090031618A (en) * 2006-07-12 2009-03-26 엘란 코포레이션, 피엘씨 Nanoparticulate Modafinil Formulations
US20090318469A1 (en) * 2006-07-14 2009-12-24 Boehringer Ingelheim International Gmbh Use of Flibanserin for the Treatment of Sexual Disorders in Females
FR2903904A1 (en) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile ASSOCIATION OF MODAFINIL AND AN ANTAGONIST OR REVERSE H3 RECEPTOR AGONIST
CL2007002214A1 (en) 2006-08-14 2008-03-07 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION IN THE FORM OF COMPRESSED, WHERE AT LEAST THE LENGTH OF THE COMPRESSED IN THE PREVIOUS STATE OF THE APPLICATION IS AT LEAST 7/12 OF THE PILOR DIAMETER OF THE PATIENT AND AFTER INGERING IT IN THE FOOD STATE, THE LENGTH OF THE COMP
EP2054041A2 (en) 2006-08-14 2009-05-06 Boehringer Ingelheim International GmbH Formulations of flibanserin and method for manufacturing the same
IL197129A (en) * 2006-08-25 2014-08-31 Boehringer Ingelheim Int Controlled release system and method for manufacturing the same
US20080181966A1 (en) * 2006-10-18 2008-07-31 Cephalon, Inc. Modafinil pharmaceutical compositions
CN101641090B (en) * 2006-12-19 2012-12-05 亚勒斯有限公司 Use of modafinil to treat restless leg syndrome
WO2008090742A1 (en) * 2007-01-23 2008-07-31 National University Corporation Hokkaido University Non-human animal for eye disease model
US9289403B2 (en) * 2007-03-09 2016-03-22 The Board of Trustees of the University of Arizona Use of modafinil to treat spasticity
CL2008002693A1 (en) * 2007-09-12 2009-10-16 Boehringer Ingelheim Int Use of flibanserin for the treatment of selected vasomotor symptoms of hot flashes, night sweats, mood swings, and irritability
US20090082462A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched armodafinil
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
FR2970711B1 (en) 2011-01-20 2016-03-04 Hopitaux Paris Assist Publique LAUFLUMIDE AND ITS ENANTIOMERS, PREPARATION AND THERAPEUTIC USES
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement
KR102150417B1 (en) * 2018-08-29 2020-09-01 경북대학교 산학협력단 Sleep promoting animal model by optogenetic stimulation of astrocytes in the ventrolateral preoptic area and method for screening sleep control agents using the same
GB201821066D0 (en) * 2018-12-21 2019-02-06 Univ Oxford Innovation Ltd Sleep modulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2385693A1 (en) * 1977-03-31 1978-10-27 Lafon Labor ACETAMIDE DERIVATIVES USEFUL PARTICULARLY IN THERAPEUTICS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593809B1 (en) 1986-01-31 1988-07-22 Lafon Labor BENZHYDRYLSULFINYLACETAMIDE, PROCESS FOR PREPARATION AND THERAPEUTIC USE
FR2663225B1 (en) 1990-06-14 1994-11-04 Lafon Labor NEW USE OF MODAFINIL.
FR2697162B1 (en) * 1992-10-23 1995-01-13 Lafon Labor Use of modafinil for the manufacture of a medicament for the treatment of urinary incontinence and urethro vesical sphincter disorders.
FR2707637B1 (en) 1993-06-30 1995-10-06 Lafon Labor New acetamide derivatives, their preparation process and their use in therapy.
US5618845A (en) 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
FR2771004B1 (en) 1997-11-19 2000-02-18 Inst Curie USE OF BENZHYDRYL SULFINYL DERIVATIVES FOR THE MANUFACTURE OF MEDICINAL PRODUCTS HAVING A WAKING EFFECT IN SITUATIONS OF DRUG-BASED VIGILANCE DISORDERS
CN100548290C (en) * 1999-02-24 2009-10-14 辛辛那提大学 Use of sulfamate derivatives for the treatment of impulse control disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2385693A1 (en) * 1977-03-31 1978-10-27 Lafon Labor ACETAMIDE DERIVATIVES USEFUL PARTICULARLY IN THERAPEUTICS

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"Modafinil tested in MS fatigue.", PHARMACEUTICAL JOURNAL, (6 MAY 2000) 264/7095 (686)., XP001036740 *
BILLIARD M ET AL: "Wake disorders. Part 1: Primary wake disorders.", REVUE NEUROLOGIQUE (PARIS), vol. 154, no. 2, February 1998 (1998-02-01), pages 111 - 129, XP001036602, ISSN: 0035-3787 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; XP002191700, Database accession no. prev199900081712 *
DAVIS W.M.: "Multiple sclerosis: Continuing mysteries and current management.", DRUG TOPICS, (19 JUN 2000) 144/12 (93-102)., XP001036734 *
HAYAISHI OSAMU: "Molecular mechanisms of sleep-wake regulation: A role of prostaglandin D2.", PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON B BIOLOGICAL, vol. 355, no. 1394, 29 February 2000 (2000-02-29), Feb. 29, 2000, pages 275 - 280, XP001064040, ISSN: 0962-8436 *
ONOE HIROTAKA: "Molecular and neuroanatomical mechanisms of sleep-wakefulness regulation by prostaglandins D2 and E2", FOLIA PHARMACOLOGICA JAPONICA, vol. 112, no. 6, 1998, pages 343 - 349, XP001064043 *
RAMMOHAN KOTTIL W ET AL: "Modafinil: Efficacy and safety for the treatment of fatigue in patients with multiple sclerosis.", NEUROLOGY, vol. 54, no. 7 Supp. 3, 11 April 2000 (2000-04-11), 52nd Annual Meeting of the American Academy of Neurology.;San Diego, CA, USA; April 29-May 06, 2000, pages A24, XP001036620, ISSN: 0028-3878 *
RUGINO THOMAS A ET AL: "Effects of modafinil in children with attention-deficit/hyperactivity disorder: An open-label study.", JOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY, vol. 40, no. 2, February 2001 (2001-02-01), pages 230 - 235, XP001036603, ISSN: 0890-8567 *
RUGINO THOMAS ET AL: "Modafinil in ADHD: A pilot study.", DEVELOPMENTAL MEDICINE & CHILD NEUROLOGY, vol. 42, no. Supplement 83, August 2000 (2000-08-01), 2000 Annual Meeting of the American Academy for Cerebral Palsy & Developmental Medicine, pages 14, XP001036619, ISSN: 0012-1622 *
SCAMMELL THOMAS E ET AL: "Hypothalamic arousal regions are activated during modafinil-induced wakefulness.", JOURNAL OF NEUROSCIENCE, vol. 20, no. 22, 15 November 2000 (2000-11-15), pages 8620 - 8628, XP000989746, ISSN: 0270-6474 *
SCAMMELL THOMAS ET AL: "Activation of ventrolateral preoptic neurons by the somnogen prostaglandin D2.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 13, 23 June 1998 (1998-06-23), June 23, 1998, pages 7754 - 7759, XP002191478, ISSN: 0027-8424 *
TAYLOR F B ET AL: "Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults.", JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, (2000 WINTER) 10 (4) 311-20., XP001036710 *
TERZOUDI, MARIA (1) ET AL: "Fatigue in multiple sclerosis: Evaluation and a new pharmacological approach.", NEUROLOGY, (APRIL 11, 2000) VOL. 54, NO. 7 SUPP. 3, PP. A61-A62. MEETING INFO.: 52ND ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY. SAN DIEGO, CA, USA APRIL 29-MAY 06, 2000 AMERICAN ACADEMY OF NEUROLOGY., XP001036618 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7649020B2 (en) 2002-08-09 2010-01-19 Cephalon France Modafinil polymorphic forms

Also Published As

Publication number Publication date
NO20020772D0 (en) 2002-02-15
CA2689735A1 (en) 2001-02-22
NO20020772L (en) 2002-02-15
CA2380673A1 (en) 2001-02-22
CA2380673C (en) 2010-03-30
US20030069313A1 (en) 2003-04-10
NO331307B1 (en) 2011-11-21
IL147794A0 (en) 2002-08-14
CN1635875A (en) 2005-07-06
IL147794A (en) 2007-07-04
JP2003527320A (en) 2003-09-16
EP1253918B1 (en) 2008-10-08
AU778360B2 (en) 2004-12-02
NZ516767A (en) 2004-03-26
KR20020038726A (en) 2002-05-23
KR100728080B1 (en) 2007-06-14
US20020082301A1 (en) 2002-06-27
MXPA02001587A (en) 2003-07-21
AU6642400A (en) 2001-03-13
DE60040487D1 (en) 2008-11-20
WO2001012170A2 (en) 2001-02-22
HK1051006A1 (en) 2003-07-18
US6346548B1 (en) 2002-02-12
DK1253918T3 (en) 2008-12-08
ES2313902T3 (en) 2009-03-16
CN100450475C (en) 2009-01-14
US6488164B2 (en) 2002-12-03
CY1109079T1 (en) 2014-07-02
JP5542291B2 (en) 2014-07-09
ATE410157T1 (en) 2008-10-15
EP1253918A2 (en) 2002-11-06
PT1253918E (en) 2008-11-20
US7087647B2 (en) 2006-08-08
BR0013555A (en) 2007-03-27

Similar Documents

Publication Publication Date Title
WO2001012170A3 (en) Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
WO1999045949A3 (en) Use of follistatin to modulate gdf-8 and bmp-11
CA2165824A1 (en) Use of modafinil for the treatment of sleep apnea and ventilation problems of central origin
ID28916A (en) TREATMENT OF BILLS AND BEHAVIOR RELATING TO BILLS
NZ502527A (en) Catalytic monoclonal antibodies raised to proteins in aggregated form, and use to treat alzheimers, atherosclerosis, amyloidosis and prions disease
AU9262598A (en) Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
PL330496A1 (en) Methods of and compositions for treating and preventing tumours, disorders associated with tumours as well as cachexy
CA2391808A1 (en) Method for treatment of symptoms of central nervous system disorders
WO2003057698A3 (en) Spiroazacyclic compounds as monoamine receptor modulators
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
WO2003102016A3 (en) Amyloid peptide inactivating enzyme to treat alzheimer's disease
WO2004015130A3 (en) Modulators of rabggt and methods of use thereof
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
AU2003217652A1 (en) Methods for continuous performance testing
AU2384500A (en) Compounds, methods of screening and methods of treatment for central and peripheral nervous system disorders
WO1999048489A3 (en) Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
PL335752A1 (en) Anti-fas antibodies
WO2000038669A3 (en) Use of naloxone for preventing and treating the degeneration of neurons
WO2003056897A3 (en) Highly phosphorylated acid beta-glucocerebrosidase and methods of treating gaucher's disease
MY126607A (en) Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
AUPP379698A0 (en) Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions
WO2000000159A3 (en) Method of treatment for dermatological disorders
EP0745597A3 (en) Novel melatonergic indanyl piperazines or homopiperazines
WO2004058154A3 (en) Method of identifying therapeutic agents
WO2001072955A3 (en) Regulation of human nedd1-related protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 147794

Country of ref document: IL

Ref document number: 516767

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/128/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002/00807

Country of ref document: ZA

Ref document number: 200200807

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2380673

Country of ref document: CA

Ref document number: 008111820

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2000954081

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/001587

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020027001958

Country of ref document: KR

Ref document number: 66424/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020027001958

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000954081

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 516767

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 516767

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 66424/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: PI0013555

Country of ref document: BR